The PODO Trial
Trial To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis
Breve descripción
The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio).
Médico del ensayo/Coordinador del estudio
Alan McMahon
Correo electrónico Número de teléfono (780) 407-2077Nombre del sitio
University of Alberta Hospital
University of Alberta Hospital, 8440-112 Street Northwest, OPR 3T1.24, Edmonton, AB T6G 2B7, Canada
Nombre del patrocinador
Pfizer Inc.
Nombre del fármaco del estudio
PF-06730512
Matrícula estimada
44
Fecha estimada de finalización
May, 2023
The PODO Trial
Trial To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis
Breve descripción
The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio).
El ensayo es para personas con
Primary focal segmental glomerulosclerosis (FSGS)
Objetivo del estudio
To evaluate the safety, tolerability, and possibly efficacy of PF-06730512 in patients with FSGS.
Qué implica para el paciente?
Patients will participate for 13 weeks, receiving an intravenous infusion of the study drug weekly.
Sobre el medicamento o la intervención
PF-06730512 works as an antagonist, meaning it possibly reduces the biologic activity that is associated with FSGS.